title: A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
abstract: The anticancer agent docetaxel shows significant inter-individual variation in its pharmacokinetic and toxicity profile. Thalidomide is an active anticancer agent and also shows wide pharmacological variation. Past pharmacogenetic research has not explained this variation. Patients with prostate cancer enrolled in a randomized phase II trial using docetaxel and thalidomide versus docetaxel alone were genotyped using the Affymetrix DMET 1.0 platform, which tests for 1256 genetic variations in 170 drug disposition genes. Genetic polymorphisms were analyzed for associations with clinical response and toxicity. In all, 10 single-nucleotide polymorphisms (SNPs) in three genes were potentially associated with response to therapy: peroxisome proliferator-activated receptor-delta (PPAR-delta), sulfotransferase family, cytosolic, 1C, member 2 (SULT1C2) and carbohydrate (chondroitin 6) sulfotransferase 3 (CHST3). In addition, 11 SNPs in eight genes were associated with toxicities to treatment: spastic paraplegia 7 (pure and complicated autosomal recessive) (SPG7), CHST3, cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6), N-acetyltransferase 2 (arylamine N-acetyltransferase) (NAT2), ATP-binding cassette, sub-family C (CFTR/MRP), member 6 (ABCC6), ATPase, Cu++ transporting, alpha polypeptide (ATP7A), cytochrome P450, family 4, subfamily B, polypeptide 1 (CYP4B1) and solute carrier family 10 (sodium/bile acid cotransporter family), member 2 (SLC10A2). Genotyping results between drug metabolizing enzymes and transporters (DMET) and direct sequencing showed >96% of concordance. These findings highlight the role that non-CYP450 metabolizing enzymes and transporters may have in the pharmacology of docetaxel and thalidomide.
authors.affiliation: Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA. deekenj@georgetown.edu
authors.forename: J F
authors.initials: JF
authors.lastname: Deeken
authors.forename: T
authors.initials: T
authors.lastname: Cormier
authors.forename: D K
authors.initials: DK
authors.lastname: Price
authors.forename: T M
authors.initials: TM
authors.lastname: Sissung
authors.forename: S M
authors.initials: SM
authors.lastname: Steinberg
authors.forename: K
authors.initials: K
authors.lastname: Tran
authors.forename: D J
authors.initials: DJ
authors.lastname: Liewehr
authors.forename: W L
authors.initials: WL
authors.lastname: Dahut
authors.forename: X
authors.initials: X
authors.lastname: Miao
authors.forename: W D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D000328:Adult; D000368:Aged; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D009919:Orchiectomy; D047494:PPAR delta / Q000235:genetics*; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D015238:Sulfotransferases / Q000235:genetics*; D043823:Taxoids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013792:Thalidomide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000097811:Carbohydrate Sulfotransferases
chemical_list: D000077143:Docetaxel; D047494:PPAR delta; D015238:Sulfotransferases; D043823:Taxoids; D013792:Thalidomide; D000097811:Carbohydrate Sulfotransferases; C513319:SULT1C2 protein, human